Nanoporous adsorbents are promising materials to augment the efficacy of haemodialysis for the treatment of end stage renal disease where mortality rates remain unacceptably high despite improvements in membrane technology. Complications are linked in part to inefficient removal of protein bound and high molecular weight uremic toxins including key marker molecules albumin bound indoxyl sulphate (IS) and p-cresyl sulphate (PCS) and large inflammatory cytokines such as IL-6. The following study describes the assessment of a nanoporous activated carbon monolith produced using a novel binder synthesis route for scale up as an in line device to augment haemodialysis through adsorption of these toxins.
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Introduction
Nanoporous adsorbents offer a potential method by which to address the life-reducing complications associated with poor removal of protein bound and high molecular weight uraemic toxins during haemodialysis. Whilst more than two million patients with end stage renal disease (ESRD) are treated by haemodialysis worldwide mortality rates remain high.
Almost half of all patients who receive a diagnosis of ESRD die within three years, most commonly as a result of cardiovascular co-morbidity followed by infection (1) (2) (3) (4) .
Haemodialysis is a life sustaining therapy and an efficient method for removing excess fluid and highly water soluble small molecules such as ionic solutes and urea from blood. Urea is known to hydrolyse into cyanate and form carbamylated haemoglobin (5) (6) (7) (8) and other carbamylated proteins and lipoproteins. However, there is debate as to whether urea is a "uraemic" toxin or whether its use as a marker of dialysis adequacy actually correlates with adequate removal of uraemic toxins with the most damaging effects on tissue physiology (9, 10) . Urea is rapidly cleared during standard haemodialysis whereas other uraemic retention solutes, particularly protein bound and high molecular weight molecules, are minimally cleared resulting in retention in ESRD patients (11) . Indoxyl sulphate (IS) and p-cresyl sulphate (PCS) are protein bound uraemic toxins derived from protein metabolism (12) .
They have been shown, both within in vitro and in animal models, to cause endothelial damage and cardiovascular disease, and are associated with increased mortality in ESRD patients (12) (13) (14) (15) (16) (17) . To date a suitable method to remove these and the many other poorly removed protein bound and high molecular uraemic toxins (17) remains to be found (11, 18) .
Addition of an adsorption device into the standard haemodialysis circuit has great potential to improve removal of such toxins (2, (19) (20) (21) (22) (23) . Synthetic, activated carbon adsorbents offer 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Page 3 of 32 AUTHOR SUBMITTED MANUSCRIPT -BMM-101590. R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t considerable advantages over other polymer based systems. They outperform other adsorbents through the existence of a highly developed internal surface area which is suitable for non-specific adsorption of predominantly hydrophobic, organic molecules. Early studies using various granular AC formulations from a range of natural sources showed some success but were ultimately constrained by variable performance, poor haemocompatibility particularly related to platelet loss, pressure drop and poor adsorption of larger biological molecules when coated (24) (25) (26) (27) (28) (29) (30) (31) . Advances in production technology using synthetic pre-cursors have improved activated carbon performance through carefully controlled formulation, carbonisation and activation procedures allowing the production of mechanically strong microbeads with an internal surface area of over 1500 m 2 g -1 (32) (33) (34) .
Additionally it is possible to significantly increase capacity for the removal of protein bound and high molecular weight uraemic toxins through the development of nanopores with diameter in the range of 10-100 nm (35) (36) (37) (38) . This structure can be maintained and potential for pressure drop reduced by the production of activated carbon monoliths, formed as extruded cylinders with numerous micro-diameter channels along which blood flows. We have previously shown that nanoporous activated carbon monoliths can adsorb protein bound uraemic and high molecular weight toxins which are poorly removed by haemodialysis alone (39) . However, a monolith synthesis route which enabled the production of monoliths with attrition resistance and adsorptive capacity on scale up to a clinically relevant size was not possible using the previous synthesis route. The aim of the current study was to assess monoliths produced by a novel lignin binder route for haemocompatibility using ex vivo healthy donor and a niave rat haemoperfusion model.
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Materials and Methods
Monolith synthesis
Monoliths were synthesised using a novolac phenol-formaldehyde resin pre-cursor dissolved in a pore-forming solvent, ethylene glycol, together with a cross-linking agent, hexamethylenetetramine, and lignin binder. The ratio of lignin binder to nanoporous resin was optimised to a wt% ratio of 25:75. The pre-polymer solution was cured and the resulting resin cake was crushed, washed and dried to remove excess pore former then milled and formed into a dough for extrusion. The resulting monoliths were carbonised at 700 °C and activated in carbon dioxide at temperatures of up to 880°C. Nanoporosity was controlled primarily by initial resin pore-former composition and the unique phase separation that occurs during the curing stage. Small monoliths were prepared with a diameter of 7 mm, length of 95 mm and contained 30 square micro-channels. Large monoliths were prepared with a diameter of 30 mm and length of 225 mm and contained 600 square micro-channels with a diameter of 300 µm. The monoliths were encased in heat shrink polyolefin tubes supplied by RS Components Ltd (Northamptonshire, UK). The process sealed Leuer lock fittings to the ends of the monoliths prior to the perfusion studies (fig 1a and 1b) .
Physical characterisation of small and large monoliths
The surface and internal porous morphology of the resultant monolithic materials were characterised by scanning electron microscopy (SEM) using a Sigma field emission gun Page 5 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Page 5 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t Figure 1 (a) Small and large monoliths were produced using a novel lignin binder route with dimensions of 0.7 cm x 9.5 cm and 2.8 x 22.5 cm (diameter by length) and microchannel numbers of 30 channels and 600 channels respectively (b) The monoliths were encased in heat shrink polyolefin tubes (c) In vitro plasma and whole blood experiments were conducted, perfusing fluid through the monolith microchannels at a flow rate of 5ml/min for the small monolith studies and 300 ml/min for the large monolith studies (d) A naive rat haemoperfusion model was used to carry out an in vivo safety assessment of the small monoliths (FEG)-SEM microscope (Carl Zeiss NTS, Cambridge, UK). The definition of pore size in nanoporous materials according to the International Union of Pure and Applied Chemistry (IUPAC) is that micropores are smaller than 2 nm in diameter, mesopores 2-50 nm and macropores larger than 50 nm. The carbons used in this study were predominantly micromacroporous. Prior to measurement, the hierarchically porous monolithic materials were A c c e p t e d M a n u s c r i p t dried under vacuum at 150°C overnight. The pore size distribution data was determined using a PoreMaster mercury intrusion porosimeter (Quantachrome Instruments Ltd, Hook, UK). Surface area was determined using an Autosorb-1 gas sorption analyser, (Quantachrome Instruments, USA) using Quantachrome data analysis software (Quantachrome ASiQwin) and the Brunauer, Emmett and Teller (BET) method.
Adsorption of marker uraemic toxins by the small monoliths
The small monoliths were primed with saline solution for 30 minutes at a flow rate of 5 ml/min. A 20 ml volume of fresh frozen human plasma (Cambridge Bioscience) was spiked with IS (125 µM), PCS (250 µM) and IL6. The spiked plasma solution underwent continuous circulation through the monoliths and samples were collected over time. IS and PCS concentrations were measured by HPLC using a method described in (39) and IL6 concentration was measured by ELISA according to manufacturer's instructions using a plasma dilution of 1:5 (BD Biosciences). A c c e p t e d M a n u s c r i p t
2.4Haemocompatibility testing of small monoliths
Complement activation
The presence of C3a, C4a and C5a was measured in plasma prepared from EDTA anticoagulated blood by enzyme linked immunosorbent assay (ELISA) (BD Biosciences).
ELISAs were carried out according to manufacturer's instructions issuing a 1 in 2000 dilution for C3a and C4a and a 1 in 40 dilution for C5a.
Platelet activation
The presence of PAC-1 and CD62 platelet activation markers (BD Biosciences UK) was measured in sodium citrate anticoagulated donor blood samples pre-and post-perfusion through monolith and tubing only controls using flow cytometry. The first 2 mL blood was drawn and discarded. threshold of 10'000 to collect 10'000 events on the platelet gate.
Granulocyte activation
Granulocyte activation was measured by testing lithium heparin anticoagulated donor blood samples for the presence of CD14/CD11b markers (Biolegend, UK) using flow cytometry.
Positive control samples were prepared by incubating blood samples with interleukin 6 (IL-6) (50 ng/mL) and interleukin 8 (IL-8) (50 ng/mL) for 60 minutes. Blood samples (100 µL)
were incubated with PE/CD14 (20 µL) and APC/CD11b (20 µL) antibody cocktails for 20 minutes. Stained blood samples were incubated with lyse/fix buffer (1.5 mL) in the dark for 30 minutes prior to centrifugation at 600g for 6 min, removal of supernatant and washing of cells in 2 mL stain buffer. Cells were pelleted and resuspended in 300 µL stain buffer for A c c e p t e d M a n u s c r i p t analysis using flow cytometry. The flow cytometer was set to medium flow rate, with a forward scatter (FSC) threshold of 80'000 to collect 10'000 events.
T cell activation
T cell activation was assessed in EDTA anticoagulated blood samples by measuring the activation of STAT3 and STAT 5 intracellular phosphorylation pathways using flow cytometry. Whole blood samples (200 µL) were lysed, permeabilised and stained by incubating with PerCP/CD3, Alexa488/CD8, PE/CD4 antibody cocktail (20 µL) and Alexa647/STAT3 or STAT5 (20 µL) for 1 hour. Positive control samples were prepared using an IL-6 (50 ng/mL) and IL-8 (50 ng/mL) spike for STAT3 activation and interleukin 2 (IL-2) (50 ng/ml) spike for STAT5 activation followed by incubation for 60 minutes. Cells were washed and resuspended in 200 µL stain buffer for analysis using flow cytometry with setting as for the granulocyte activation assay.
Adsorption of uraemic toxins by the large monoliths
Large monoliths (n=3) were pre-conditioned with intravenous infusion saline solution (0.9% NaCl, 0.15% KCl & 0.2% MgCl) (Baxter) for 30 minutes. A 400 mL volume of blood, anticoagulated with sodium heparin and commercially supplied by Cambridge Biosciences, was spiked with 1000 pg/mL IL-6 and tumor necrosis factor alpha (TNF-α), 125 µM IS and 250 µM PCS and continuously perfused through the monolith or tubing controls for 60 minutes at a flow rate of 300 ml/min (LaboVAR 225 pump, Möller Medical GmbH Fulda Germany).
Samples were collected after 0, 5, 30, 60 min. IS and PCS concentrations were measured by HPLC using a method described in (39) and IL6/TNF−α concentration was measured by ELISA according to manufacturer's instructions using a dilution of 1:5 (BD Biosciences).
Platelet activation was measured in the plasma derived from the timed blood samples as described in section 2.5. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Page 10 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t biochemistry (glucose, urea, albumin, total protein, ALT, AST, creatinine) was assessed using an automated COBAS system (Roche, UK) following manufacturer's instructions.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism 6.05 software and two-way ANOVA with Tukey's multiple comparison tests.
Results
Physical characterisation of the large and small monoliths
The synthesis and activation process resulted in a well-defined distribution of transport microchannels running in parallel along the length of the monoliths (fig 2a-c) . The internal structure of the carbon monolith walls was visible in the SEMs as larger macroporous and smaller nanoporous domains. The mercury porosimetry pore size distribution plot indicated nanoporous domains in the 20-100 nm range in both the small and large monoliths with mean peak porosity of 55.6 nm and 62.1 nm respectively (fig 2d) . The BET surface area was calculated by gas nitrogen porosimetry to be 1117 m 2 g -1 in the small monoliths and 1056 m 2 g -1 in the large monoliths. A c c e p t e d M a n u s c r i p t Figure 2 (a) Scanning electron micrograph showing microchannel geometry and (b) nanoporous domains within the walls of the small and large monoliths (c) Mercury pore size distribution plots indicated consistent meso-macroporosity in the small and large monoliths with a mean pore size of 56 nm and 62 nm respectively and S BET surface area calculated by gas nitrogen porosimetry of 1117 and 1056 m 2 /g respectively
Adsorption of marker uraemic toxins by the small monoliths
The small monoliths synthesised using a 25% lignin binder were able to adsorb uraemic toxins IS and PCS, reducing them to neglible levels and reduced IL-6 concentration by 80%
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Page 12 of 32 AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1
Haemocompatibility testing of the small monoliths
Complement activation
Blood perfused through the small monoliths over time did not cause significant complement activation when compared to the negative, tubing only control (p>0.05) (Fig 4a-c) . Some complement activation was observed at baseline and a slight increase occurred in both the monolith and tubing only controls over the 60 minute perfusion cycle. However, this was significantly less than that of the zymosan A activated positive controls in which complement fragment concentrations increased from 1.5 ng/mL to 4.1 ng/mL for C3a (p< 0.0001) (fig 4a) , 1.6 ng/mL to 3.3 ng/mL for C4a (p<0.05) (fig 4b) and 3.9 pg/mL to 43.5 pg/mL for C5a (p< 0.0001) (Fig. 4c) . C5a concentration detected in the plasma was in the picogram range and significantly lower than that for C3a and C4a which was in the ng range. A c c e p t e d M a n u s c r i p t C3a in plasma (ng/ml) Figure 4 Perfusion of freshly drawn healthy donor blood through the small monoliths over 60 minutes stimulated no significant complement activation measured using (a) C3a (b) C4a and (c) C5a activation markers, no significant platelet activation measured using (d) PAC-1 and (e) CD62P activation markers and no significant T cell activation, measured using phosphorylated (f) STAT3 and (g) STAT5 protein expression when compared to tubing only controls in comparison to the zymosan A, PMA and cytokine stimulated positive controls (mean+/-SEM, n=3), ** p < 0.01, **** p<0.0001
Platelet activation
A platelet sub-population was isolated from the total blood cell population using a RPhycoerythrin (PE) fluorophore conjugated CD61 antibody against the platelet surface 
Granulocyte activation
No significant difference in granulocyte activation was observed between the monolith and tubing only controls following 60 minutes perfusion, although granulocyte activation did occur in both circuits (data not shown). Granulocyte activation, measured by elevated CD11b expression, occurred over 30 and 60 minutes blood perfusion through both monoliths and control but was less than that measured in the cytokine stimulated positive control (SEM±, n=3). 8% granulocyte activation was measured at baseline, 20 ± 4% after 30 minutes perfusion and 70 ± 13% after 60 minutes perfusion in both the small monolith and tubing only samples.
T cell activation
The PE conjugated CD3 antibody was used to identify the T cell subpopulation. Alexa 647 conjugated STAT3 and STAT5 antibodies were used to identify the post-perfusion, activated T cells, IL6/IL8 (50 ng/mL) activated STAT 3 positive control and IL2 activated STAT 5 positive control (fig 4f,g) . No up regulation of intracellular STAT phosphorylation pathways was detected following blood perfusion through the small monoliths over 60 minutes. Negligible levels of STAT3 phosphorylation and STAT5 phosphorylation and levels of 10-20% were 
Blood biochemistry and coagulometry
Haemoglobin and haematocrit values, blood cell count, ionic solutes, urea, creatinine, total protein, albumin, fibrinogen and coagulometry measures remained in normal range and were not removed significantly by blood perfusion through the small monoliths (Table 1) .
Limited reduction in platelet count, total protein and albumin concentration occurred 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Page 16 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t Table 1 . Healthy donor blood perfused through the small monoliths at 5 ml/min for 90 mins did not produce significant changes in blood cell count (WBC, RBC, PLT), haematocrit (HCT) and haemoglobin (HB) measures of haemolysis, urea, creatinine, total protein and APPT and INR measures of coagulation compared to tubing only controls (mean+/-SD, n=3). A c c e p t e d M a n u s c r i p t 5a-d). The monoliths adsorbed IL-6 and TNF-α, significantly reducing IL-6 concentration from 711 to 162 pg/mL and TNF−α from 1070 to 441 pg/mL over a 90 minute perfusion cycle. A platelet activation study showed no significant activation of platelets over 90 minutes of perfusion through the monoliths and controls (fig 6) . A further study extending the perfusion cycle to 240 minutes showed continued reduction in IS, PCS and IL-6 (fig 7) .
Pre-perfusion
In vivo safety assessment of small monoliths
The in vivo monolith perfusion safety study indicated no major concerns with regard to biocompatibility. None of the studies conducted showed any evidence of coagulopathies, either in terms of excess bleeding or clotting abnormalities. The circuit was pre-filled with heparinised saline, thought there was no evidence that the monolith removed heparin form the circuit. Blood gas values remained stable throughout the duration of the study (Table   XX) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Page 18 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t percentage of PAC-1 and CD62P positive platelets was observed when comparing the monolith and tubing only control. In contrast, the PMA (200 nM) spike induced significant platelet activation (SEM±, n=3), *** p<0.001. (Table 2) . Mean arterial blood pressure remained stable throughout the duration of the study, indicating that the animals tolerated the procedure well. Table 2 Naïve rat haemoperfusion data showing the results from blood gas analyses, plasma biochemistry and direct measurement of the mean arterial pressure. Data were analysed using one way ANOVA. * p<0.05, ** p<0.01, ***p<0. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Page 20 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t 
Discussion
The study provides evidence to support the haemocompatibility and efficacy of a scaleable nanoporous activated carbon monolith device for potential use to augment current haemodialysis therapy. A range of haemocompatibility tests using healthy donor blood samples and a small animal blood perfusion modelling study demonstrated that the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Page 21 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t monoliths are safe for use in direct blood contact. A novel lignin binder synthesis route was used to successfully scale up the device to a clinically feasible size without reducing adsorptive efficacy for marker protein bound and high molecular weight uraemic toxins.
Whilst no previous studies on nanoporous activated carbon monoliths with the porous range demonstrated in this study have been described, in vitro study data exists for carbons in bead form include carbide derived carbons, phenolic resin derived activated carbons and carbon incorporated into a mixed matrix hallow fibre membrane form (40) (41) (42) . The beads showed some efficacy in spiked plasma studies but offer no solution to the challenges of direct blood contact and pressure drop. Mixed membrane carbon incorporation offers an interesting alternative but may limit contact area for sufficient adsorption of high molecular weight molecules. In mixed membrane form significant IS and PCS removal was reported but no data was reported for high molecular weight species potentially because the membrane cut off limits direct contact. Previous studies comparing synthetic resin derived carbon bead activation burn off and adsorptive efficacy reported reduction of high molecular weight cytokine TNF matching that shown previously for CDCs but data is limited to batch adsorption studies from plasma. Within the current study a phenolic resin derived activated carbon monolith rather than bead based device was shown to reduce IS and PCS levels in spiked whole blood to negligible levels and IL6 and TNF levels by 80% and 60% respectively indicating a scaleable efficacy compared to bead based alternatives. The monolith design solves issues of haemocompatibility and pressure drop across the adsorbent device without resorting to coating with potential subsequent reduction in the molecular weight cut-off and adsorptive profile.
There are many advantages in adapting the activated carbon form to a monolithic structure for direct blood perfusion but also many challenges in maintaining porous profile and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Page 22 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t adsorptive efficacy. Previous tests using a small monolith prototype and haemodialysis patient blood samples indicated that adsorption of protein bound and middle molecules was dependent on creating nanopores in the 2-100 nm range since adsorption of these solutes in carbon monoliths with narrow nanopores of <2 nm was limited (39) . The challenge in scaling up the monolith was to maintain nanoporosity but also to design the monolith channel parameters to balance maximum adsorption with appropriate internal fluid dynamics (43) . This was achieved in the current device iteration by using a constant 0.3 mm microchannel channel size. A short diffusion distance was provided for access to the internal porous surface area in the walls of the monolith and a micro-channel structure capable of minimising shear stress, maintaining laminar flow and thus reducing red blood cell fragility, haemolysis, platelet activation and thrombus formation. Previous studies with activated carbon granules containing narrow nanopores of < 2 nm have highlighted the tendency for excessive pressure drop, platelet consumption, albumin loss and potential for carbon fines release (30) . The introduction of a monolithic design was therefore integral to minimise the tendency for flow irregularities, pressure drop and impact on blood cell fragility, platelet loss and protein adhesion.
Binding of plasma proteins occurs as soon as blood contacts a foreign surface. Dominant plasma proteins albumin, fibrinogen and IgG coat a surface immediately but with a dynamic exchange with other plasma proteins over time (44) . Protein surface coating in the extracorporeal circuit becomes problematic if proteins are denatured and expose activation sites for inflammatory pathway activation or in some cases if a negatively charged surface induces contact activation (44) . Protein surface adhesion may also form a passivating layer, limiting any further inflammatory response. In the current study blood albumin and fibrinogen concentrations were reduced on contact with the monoliths However, total reported that the TNF-α trimer undergoes reversible dissociation into three monomeric units in contact with hydrophobic surfaces and therefore smaller molecules of IL-6 and TNF−α monomer (17 kDa) could be adsorbed predominantly within the nanoporous domains of the monoliths inaccessible to albumin (45) . Results confirm no significant impact on total protein, electrolyte and haemolysis parameters using healthy donor blood perfused through the small monoliths over time. Albumin and platelet reduction was slight using the healthy blood samples in contrast to a previous study using post-haemodialysis blood samples where a greater reduction in platelet count and albumin concentration was observed (39) . A number of additional variables including differences in blood sample handling and monolith formulation may have influenced the heightened propensity for haemodialysis blood sample proteins and platelets to adhere but the results also support the premise that haemodialysis patient blood is primed for inflammation.
The haemocompatibility tests were carried out on the small monolith prototypes according to ISO 10993 for blood contacting medical devices assessing platelet activation, granulocyte activation, activation of t-cell intracellular phosphorylation pathways for STAT3 and STAT5 using flow cytometry, complement fragment concentration for C3a, C4a, C5a using ELISA 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   Page 24 of 32  AUTHOR SUBMITTED MANUSCRIPT -BMM-101590.R1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t and coagulometry assays measuring pro-thrombin, APPT clotting times and fibrinogen concentration. The signal transducer and activator of transcription (STAT) family are a group of proteins activated by cytokines and growth factors through receptor associated kinase phosphorylation followed by dimerization, translocation into the nucleus and transcription of genes related to cell proliferation and the inflammatory response. They were used in this study as the earliest indicator of T-cell activation on inflammatory stimulus by the monoliths. Some complement activation and in particular granulocyte activation was detected at the 60 minute time point for both monolith and tubing only negative controls.
Complement activation is known to occur routinely on exposure to a foreign surface within haemodialysis, cardiopulmonary bypass and apheresis via the alternative pathway (46) (47) (48) .
The small, cationic peptides C3a, C4a and C5a are anaphylatoxins which are free in the plasma and bind to neutrophils and monocytes to promote ROS production, cytokine release and cell hyper-adhesion. Activation was no more than the tubing only controls and was markedly limited when compared to the zymozan A activated, positive control blood samples, indicating that the artificial surfaces within the perfusion model itself and not the monoliths promoted some activation of inflammatory pathways.
The large monoliths maintained adsorptive efficacy for the uraemic toxins IS and PCS and cytokines IL-6 and TNF−α οn scale up and at haemodialysis flow rates with minimal pressure drop. Further work is required to establish breakthrough parameters and the impact of rebound release on adsorption but the current study indicates that an adsorptive equilibrium is maintained over 4 hours perfusion time. The broad spectrum adsorptive capacity of the activated nanoporous carbon monoliths for organic molecules indicates that these monoliths will have great capacity to remove other poorly removed protein bound and middle molecule uraemic toxins from the growing family of uraemic toxins known to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d M a n u s c r i p t remain after standard haemodialysis treatments and represented by these marker molecules.
In summary, whilst haemodialysis patients have an immunosuppressive and altered haemostatic balance so that blood cell fragility and inflammatory response on contact with foreign surfaces will inevitably be hypersensitised toward inflammation (49) the results of the current study show that, using healthy donor blood, a nanoporous activated carbon monolith does not exacerbate blood cell activation according to ISO 10993 haemocompatibility measures. Haemocompatibility was also demonstrated using an in vivo haemoperfusion safety model where no disruption of blood biochemistry or coagulopathy occurred. The scaled up device maintained the internal nanoporous structure necessary to augment haemodialysis efficacy through broad spectrum adsorption of small, protein bound and high molecular weight uraemic toxins.
Conclusion
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